These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
238 related items for PubMed ID: 16784972
1. Effects of raloxifene on lipid and lipoprotein levels in postmenopausal osteoporotic women with and without hypertriglyceridemia. Dayspring T, Qu Y, Keech C. Metabolism; 2006 Jul; 55(7):972-9. PubMed ID: 16784972 [Abstract] [Full Text] [Related]
2. Effects of raloxifene and low-dose simvastatin coadministration on plasma lipids in postmenopausal women with primary hypercholesterolemia. Insull W, Davidson MH, Kulkarni PM, Siddhanti S, Ciaccia AV, Keech CA. Metabolism; 2005 Jul; 54(7):939-46. PubMed ID: 15988705 [Abstract] [Full Text] [Related]
3. Differential effects of raloxifene and continuous combined hormone replacement therapy on biochemical markers of cardiovascular risk: results from the Euralox 1 study. Nickelsen T, Creatsas G, Rechberger T, Depypere H, Erenus M, Quail D, Arndt T, Bonnar J, Euralox 1 Study Group. Climacteric; 2001 Dec; 4(4):320-31. PubMed ID: 11770189 [Abstract] [Full Text] [Related]
4. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene. McClung MR, Siris E, Cummings S, Bolognese M, Ettinger M, Moffett A, Emkey R, Day W, Somayaji V, Lee A. Menopause; 2006 Dec; 13(3):377-86. PubMed ID: 16735934 [Abstract] [Full Text] [Related]
5. Effects of conjugated equine estrogens or raloxifene on lipid profile, coagulation and fibrinolysis factors in postmenopausal women. Dias AR, Melo RN, Gebara OC, D'Amico EA, Nussbacher A, Halbe HW, Pinotti JA. Climacteric; 2005 Mar; 8(1):63-70. PubMed ID: 15804733 [Abstract] [Full Text] [Related]
6. A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women. Reid IR, Eastell R, Fogelman I, Adachi JD, Rosen A, Netelenbos C, Watts NB, Seeman E, Ciaccia AV, Draper MW. Arch Intern Med; 2004 Apr 26; 164(8):871-9. PubMed ID: 15111373 [Abstract] [Full Text] [Related]
7. HMR 3339, a novel selective estrogen receptor modulator, reduces total cholesterol, low-density lipoprotein cholesterol, and homocysteine in healthy postmenopausal women. Vogelvang TE, Mijatovic V, Kenemans P, Teerlink T, van der Mooren MJ. Fertil Steril; 2004 Dec 26; 82(6):1540-9. PubMed ID: 15589857 [Abstract] [Full Text] [Related]
8. Effect of raloxifene on serum lipids for type 2 diabetic menopausal women with or without statin treatment. Matsumura M, Monden T, Nakatani Y, Shimizu H, Domeki N, Yanagi K, Ikeda S, Kawagoe Y, Kasai K. Med Princ Pract; 2010 Dec 26; 19(1):68-72. PubMed ID: 19996623 [Abstract] [Full Text] [Related]
9. Effects of increasing doses of atorvastatin on the atherogenic lipid subclasses commonly associated with hypertriglyceridemia. Karalis DG, Ishisaka DY, Luo D, Ntanios F, Wun CC. Am J Cardiol; 2007 Aug 01; 100(3):445-9. PubMed ID: 17659926 [Abstract] [Full Text] [Related]
10. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women. Zegura B, Guzic-Salobir B, Sebestjen M, Keber I. Menopause; 2006 Aug 01; 13(4):643-50. PubMed ID: 16837886 [Abstract] [Full Text] [Related]
11. A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women. Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud C. J Bone Miner Res; 1996 Jun 01; 11(6):835-42. PubMed ID: 8725181 [Abstract] [Full Text] [Related]
12. Plasma lipoproteins in soy-treated postmenopausal women: a double-blind, placebo-controlled trial. Vigna GB, Pansini F, Bonaccorsi G, Albertazzi P, Donegà P, Zanotti L, De Aloysio D, Mollica G, Fellin R. Nutr Metab Cardiovasc Dis; 2000 Dec 01; 10(6):315-22. PubMed ID: 11302006 [Abstract] [Full Text] [Related]
13. Lipid and lipoprotein profile in physiological pregnancy. Lippi G, Albiero A, Montagnana M, Salvagno GL, Scevarolli S, Franchi M, Guidi GC. Clin Lab; 2007 Dec 01; 53(3-4):173-7. PubMed ID: 17447654 [Abstract] [Full Text] [Related]
14. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance. Sasaki J, Ikeda Y, Kuribayashi T, Kajiwara K, Biro S, Yamamoto K, Ageta M, Kobori S, Saikawa T, Otonari T, Kono S. Clin Ther; 2008 Jun 01; 30(6):1089-101. PubMed ID: 18640465 [Abstract] [Full Text] [Related]
15. Beneficial effects of raloxifene and atorvastatin on serum lipids and HDL phospholipids levels of postmenopausal women. Piperi C, Kalofoutis C, Skenderi K, Economidou O, Kalofoutis A. J Obstet Gynaecol; 2004 Jun 01; 24(4):414-9. PubMed ID: 15203583 [Abstract] [Full Text] [Related]
16. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis. Burshell AL, Song J, Dowsett SA, Mershon JL, Delmas PD, Secrest RJ, Cauley JA. Curr Med Res Opin; 2008 Mar 01; 24(3):807-13. PubMed ID: 18254988 [Abstract] [Full Text] [Related]
17. Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia. Maki KC, McKenney JM, Reeves MS, Lubin BC, Dicklin MR. Am J Cardiol; 2008 Aug 15; 102(4):429-33. PubMed ID: 18678300 [Abstract] [Full Text] [Related]
18. The effect of hormone replacement therapy on the levels of serum lipids, apolipoprotein AI, apolipoprotein B and lipoprotein (a) in Turkish postmenopausal women. Bayrak A, Aldemir DA, Bayrak T, Corakçi A, Dursun P. Arch Gynecol Obstet; 2006 Aug 15; 274(5):289-96. PubMed ID: 16810536 [Abstract] [Full Text] [Related]
19. The effect of raloxifene on cardiac autonomic regulation in osteoporotic women. Gol M, Baris N, Guneri S, Posaci C. Am J Obstet Gynecol; 2006 May 15; 194(5):1249-54. PubMed ID: 16647907 [Abstract] [Full Text] [Related]
20. Effect of raloxifene on lowering lipid parameters in patients with osteoporosis. Miskić B, Bistrović D, Cosić V, Leko N, Balen-Jandrić M, Balen I, Samardzić P, Miskić D. Int J Clin Pharmacol Res; 2003 May 15; 23(4):107-10. PubMed ID: 15224499 [Abstract] [Full Text] [Related] Page: [Next] [New Search]